In situ vaccination for the treatment of cancer

Immunotherapy

Volumn 8, Issue 3, 2016, Pages 315-330

  Hammerich, Linda ^a   Bhardwaj, Nina ^a   Kohrt, Holbrook E ^b   Brody, Joshua D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

autologous DC; cytokine; Flt3L; in situ vaccine; oncolytic virus; TLR agonist; tumor associated antigen

Indexed keywords

CD135 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN; ONCOLYTIC HERPES VIRUS; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; CANCER VACCINE; TUMOR ANTIGEN;

BONE MARROW CELL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL MATURATION; CPG ISLAND; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VESICULOVIRUS; ANIMAL; ANTIGEN PRESENTING CELL; IMMUNIZATION; IMMUNOLOGY; NEOPLASMS; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNIZATION; NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84959324403     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.120     Document Type: Review

References (153)

1. Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Lymphoma: immune evasion strategies. Cancers (Basel) 7(2), 736-762 (2015
2. Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J. Sci. 2014, pii: 734515 (2014
3. Reichardt VL, Brossart P, Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 18(4), 235-243 (2004
4. Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J. Immunol. 167(10), 5565-5573 (2001
5. London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. J. Immunol. 164(1), 265-272 (2000
6. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev. Vaccines 12(10), 1155-1172 (2013
7. Bartlett DL, Liu Z, Sathaiah M, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer 12(1), 103 (2013
8. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-Associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 191(11), 1965-1974 (2000
9. Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J. Immunol. 169(10), 5424-5432 (2002
10. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, openlabel, randomised Phase III trial. Lancet 372(9633), 145-154 (2008
11. Huang XF, Ren W, Rollins L, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. 63(21), 7321-7329 (2003
12. Fan R, Wang C, Wang Y, et al. Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors. J. Transl. Med. 10, 101 (2012
13. Wang C, Dai Z, Fan R, Deng Y, Lv G, Lu G. HSF1 overexpression enhances oncolytic effect of replicative adenovirus. J. Transl. Med. 8, 44 (2010
14. Li JL, Liu HL, Zhang XR, et al. A Phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 16(3), 376-382 (2009
15. Alemany R. Oncolytic adenoviruses in cancer treatment. Biomedicines 2(1), 36-49 (2014
16. Bridle BW, Boudreau JE, Lichty BD, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther. 17(10), 1814-1821 (2009
17. Bridle BW, Stephenson KB, Boudreau JE, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18(8), 1430-1439 (2010
18. Kaufman HL, Ingemar Andtbacka RH, Collichio FA, et al. Primary overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol. 32(SUPPL 5s), Abstract 9008a (2014
19. Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int. J. Cancer 122(12), 2880-2884 (2008
20. Cerullo V, Diaconu I, Romano V, et al. An oncolytic adenovirus enhanced for Toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol. Ther. 20(11), 2076-2086 (2012
21. Rommelfanger DM, Compte M, Grau MC, et al. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-Treated mice. Mol. Ther. 21(2), 348-357 (2013
22. Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20(4), 749-758 (2012
23. Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14(3), 361-370 (2006
24. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-Targeted oncolytic poxvirus in humans. Nature 477(7362), 99-102 (2011
25. Breitbach CJ, Arulanandam R, De Silva N, et al. Oncolytic vaccinia virus disrupts tumor-Associated vasculature in humans. Cancer Res. 73(4), 1265-1275 (2013
26. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19(3), 329-336 (2013
27. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol. 9(6), 533-542 (2008
28. Hwang TH, Moon A, Burke J, et al. A mechanistic proofof-concept clinical trial with JX-594, a targeted multimechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19(10), 1913-1922 (2011
29. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-Tumour properties. Gene Ther. 10(4), 292-303 (2003
30. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16(15), 4005-4015 (2010
31. Hu JC, Coffin RS, Davis CJ, et al. A Phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor. Clin. Cancer Res. 12(22), 6737-6747 (2006
32. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27(34), 5763-5771 (2009
33. Kaufman HL, Kim DW, Deraffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17(3), 718-730 (2010
34. Puzanov I, Milhem MM, Ingemar Andtbacka RH, et al. Primary analysis of a Phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (IPI) in previously untreated, unresected stage IIIB-IV melanoma. J. Clin. Oncol. 32(SUPPL 5s), Abstract 9029 (2014
35. Colombo MP, Trinchieri G. Interleukin-12 in anti-Tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 155-168 (2002
36. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann. Surg. 233(6), 819-826 (2001
37. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GMCSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13(3), 253-265 (2006
38. Zhang W, Fulci G, Wakimoto H, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 15(6), 591-599 (2013
39. Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl Acad. Sci. USA 110(29), 12006-12011 (2013
40. Diaconu I, Cerullo V, Hirvinen ML, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 72(9), 2327-2338 (2012
41. Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40Lexpressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 72(7), 1621-1631 (2012
42. Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector doublearmed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 65(23), 10663-10668 (2005
43. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 12(2), 643-652 (2006
44. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61(1), 153-161 (2001
45. Lee YS, Kim JH, Choi KJ, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin. Cancer Res. 12(19), 5859-5868 (2006
46. Choi KJ, Kim JH, Lee YS, et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther. 13(13), 1010-1020 (2006
47. Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-Tumor effects of low-And high-dose cyclophosphamide. Oncol. Rep. 16(1), 141-146 (2006
48. Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19(9), 1737-1746 (2011
49. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58(10), 1627-1634 (2009
50. Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6(226), 226ra232 (2014
51. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8(1), e53745 (2013
52. Dias JD, Hemminki O, Diaconu I, et al Targeted Cancer Immunotherapy with Oncolytic Adenovirus Coding for A Fully Human Monoclonal Antibody Specific for CTLA-4. Gene Ther. 19(10), 988-998 (2012
53. Engeland CE, Grossardt C, Veinalde R, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther. 22(11), 1949-1959 (2014
54. Du T, Shi G, Li YM, et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colonystimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 21(8), 340-348 (2014
55. Rodríguez-García A, Giménez-Alejandre M, Rojas JJ, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin. Cancer Res. 21(6), 1406-1418 (2015
56. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 61(20), 7530-7535 (2001
57. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 65(13), 5958-5964 (2005
58. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin. Cancer Res. 12(8), 2568-2574 (2006
59. Guo J, Zhu J, Sheng X, et al. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int. J. Cancer 120(11), 2418-2425 (2007
60. Kolstad A, Kumari S, Walczak M, et al. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 125(1), 82-89 (2015
61. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-Tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993
62. Yizhi Y, Xuetao C, Hong L, Quanxing W, Qun T. The therapeutic effect of intratumoral injection of GM-CSF gene-modified allogenic macrophages on tumor-bearing mice. Chin. J. Cancer Res. 10(1), 1-5 (1998
63. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 95(22), 13141-13146 (1998
64. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12), 3239-3246 (2000
65. Hoeller C, Jansen B, Heere-Ress E, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J. Invest. Dermatol. 117(2), 371-374 (2001
66. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 7(1), 19-30 (2007
67. Marroquin CE, Westwood JA, Lapointe R, et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother. 25(3), 278-288 (2002
68. Morse MA, Nair S, Fernandez-Casal M, et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18(23), 3883-3893 (2000
69. Pawlowska AB, Hashino S, Mckenna H, Weigel BJ, Taylor PA, Blazar BR. In vitro tumor-pulsed or in vivo Flt3 ligandgenerated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-Transplanted mice. Blood 97(5), 1474-1482 (2001
70. Riediger C, Wingender G, Knolle P, Aulmann S, Stremmel W, Encke J. Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model. J. Cancer Res. Clin. Oncol. 139(12), 2097-2110 (2013
71. Hou S, Kou G, Fan X, et al. Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. Cancer Immunol. Immunother. 56(10), 1605-1613 (2007
72. Kreiter S, Diken M, Selmi A, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 71(19), 6132-6142 (2011
73. Bhardwaj N, Merad M, Kim-Schulze S, et al. Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a Flt3L-primed In situ vaccine for low-grade lymphoma [NCT01976585]. J. Immunother. Cancer 2(SUPPL 3), 45 (2014
74. Jahrsdörfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69(1), 81-88 (2001
75. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol. 179(4), 2493-2500 (2007
76. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 113(1), 85-94 (2009
77. Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumorspecific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123(6), 2447-2463 (2013
78. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113(15), 3546-3552 (2009
79. Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010
80. Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a Phase 1/2 study. Blood 119(2), 355-363 (2012
81. Grauer OM, Molling JW, Bennink E, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J. Immunol. 181(10), 6720-6729 (2008
82. Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Kornbluth RS. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I: C) and CD40 ligand plasmid DNA. J. Thorac. Oncol. 4(7), 802-808 (2009
83. Sharma S, Dominguez AL, Hoelzinger DB, Lustgarten J. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol. Immunother. 57(4), 549-561 (2008
84. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by In situ targeting of intratumoral DCs. J. Clin. Invest. 113(5), 774-783 (2004
85. Zhang H, Liu L, Yu D, et al. An In situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS ONE 7(5), e38111 (2012
86. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 52(13), 3528-3533 (1992
87. Adams S, Kozhaya L, Martiniuk F, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 18(24), 6748-6757 (2012
88. Henriques L, Palumbo M, Guay MP, et al. Imiquimod in the treatment of breast cancer skin metastasis. J. Clin. Oncol. 32(8), e22-25 (2014
89. Smyth EC, Flavin M, Pulitzer MP, et al. Treatment of locally recurrent mucosal melanoma with topical imiquimod. J. Clin. Oncol. 29(33), e809-811 (2011
90. Calista D, Riccioni L, Bagli L, Valenzano F. Long-Term remission of primary cutaneous neutrophil-rich CD30+anaplastic large cell lymphoma treated with topical imiquimod. A case report. J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/jdv.13070 (2015) (Epub ahead of print
91. Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br. J. Dermatol. 150(6), 1198-1201 (2004
92. Ehst BD, Dreno B, Vonderheid EC. Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream. Eur. J. Dermatol. 18(4), 467-468 (2008
93. Ariffin N, Khorshid M. Treatment of mycosis fungoides with imiquimod 5% cream. Clin. Exp. Dermatol. 31(6), 822-823 (2006
94. Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 207(1), 116-118 (2003
95. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch. Dermatol. 138(9), 1137-1139 (2002
96. Chong A, Loo WJ, Banney L, Grant JW, Norris PG. Imiquimod 5% cream in the treatment of mycosis fungoides-A pilot study. J. Dermatolog. Treat. 15(2), 118-119 (2004
97. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J. Am. Acad. Dermatol. 52(2), 275-280 (2005
98. Ardigo M, Cota C, Berardesca E. Unilesional mycosis fungoides successfully treated with imiquimod. Eur. J. Dermatol. 16(4), 446 (2006
99. Richmond HM, Lozano A, Jones D, Duvic M. Primary cutaneous follicle center lymphoma associated with alopecia areata. Clin. Lymphoma Myeloma 8(2), 121-124 (2008
100. Stavrakoglou A, Brown VL, Coutts I. Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod. Br. J. Dermatol. 157(3), 620-622 (2007
101. Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur. J. Dermatol. 16(4), 391-393 (2006
102. Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk. Lymphoma 46(6), 935-939 (2005
103. Dewan MZ, Vanpouille-Box C, Kawashima N, et al. Synergy of topical Toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 18(24), 6668-6678 (2012
104. Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 121(2), 251-259 (2013
105. Singh M, Khong H, Dai Z, et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J. Immunol. 193(9), 4722-4731 (2014
106. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of MDA-5 in type I IFN responses to polyriboinosinic: polyribocytid ylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103(22), 8459-8464 (2006
107. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I: C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28(3), 220-228 (2005
108. Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the Toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I: C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24(24), 5119-5132 (2006
109. Zhu X, Nishimura F, Sasaki K, et al. Toll-like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med. 5, 10 (2007
110. Zhu X, Fallert-Junecko BA, Fujita M, et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-Alpha and IFNgamma dependent manners. Cancer Immunol. Immunother. 59(9), 1401-1409 (2010
111. Rosenfeld MR, Chamberlain MC, Grossman SA, et al. A multi-institution Phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro. Oncol. 12(10), 1071-1077 (2010
112. Wu CY, Monie A, Pang X, Hung CF, Wu TC. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J. Biomed. Sci. 17, 88 (2010
113. Amos SM, Pegram HJ, Westwood JA, et al. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol. Immunother. 60(5), 671-683 (2011
114. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol. 36(12), 3371-3380 (2006
115. Stone GW, Barzee S, Snarsky V, et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-like receptor agonists as a treatment for melanoma. PLoS ONE 4(10), e7334 (2009
116. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol. Res. 2(8), 720-724 (2014
117. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 42(2), 145-151 (2008
118. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085), 808-812 (2006
119. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J. Exp. Med. 148(6), 1550-1559 (1978
120. Engelhardt R, Mackensen A, Galanos C, Andreesen R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J. Biol. Response Mod. 9(5), 480-491 (1990
121. Chicoine MR, Won EK, Zahner MC. Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery 48(3), 607-614; discussion 614-605 (2001
122. Won EK, Zahner MC, Grant EA, Gore P, Chicoine MR. Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme. Anticancer Drugs 14(6), 457-466 (2003
123. Mariani CL, Rajon D, Bova FJ, Streit WJ. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-Tumor response in subcutaneous RG-2 gliomas. J. Neurooncol. 85(3), 231-240 (2007
124. Maito FLDM, Souza APDD, Pereira L, et al. Intratumoral TLR-4 agonist injection is critical for modulation of tumor microenvironment and tumor rejection. ISRN Immunol. 2012, 926817 (2012
125. Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin. Cancer Res. 17(12), 3984-3992 (2011
126. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178(4), 1223-1230 (1993
127. Leonard JP, Sherman ML, Fisher GL, et al. Effects of singledose interleukin-12 exposure on interleukin-12-Associated toxicity and interferon-gamma production. Blood 90(7), 2541-2548 (1997
128. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22(8), 1389-1397 (2004
129. Mahvi DM, Henry MB, Albertini MR, et al. Intratumoral injection of IL-12 plasmid DNA-results of a Phase I/IB clinical trial. Cancer Gene Ther. 14(8), 717-723 (2007
130. ZapaLa L, Wolny R, Wachowska M, Jakóbisiak M, Lasek W. Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. Oncol. Rep. 29(3), 1208-1214 (2013
131. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60(14), 3832-3837 (2000
132. Vom Berg J, Vrohlings M, Haller S, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J. Exp. Med. 210(13), 2803-2811 (2013
133. Jackaman C, Bundell CS, Kinnear BF, et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-Associated vasculature: a novel mechanism for IL-2. J. Immunol. 171(10), 5051-5063 (2003
134. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther. 8(5), 321-332 (2001
135. Neville ME, Robb RJ, Popescu MC. In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. Cytokine 16(6), 239-250 (2001
136. Kuang M, Liu SQ, Saijo K, et al. Microwave tumour coagulation plus In situ treatment with cytokinemicroparticles: induction of potent anti-residual tumour immunity. Int. J. Hyperthermia 21(3), 247-257 (2005
137. Hoffman DM, Figlin RA. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J. Urol. 18(2), 152-156 (2000
138. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-Tissue melanoma metastases. Br. J. Cancer 89(9), 1620-1626 (2003
139. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116(17), 4139-4146 (2010
140. Hodi FS, O'day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
141. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011
142. Tuve S, Chen BM, Liu Y, et al. Combination of tumor sitelocated CTL-Associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 67(12), 5929-5939 (2007
143. Simmons AD, Moskalenko M, Creson J, et al. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol. Immunother. 57(8), 1263-1270 (2008
144. Fransen MF, Van Der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 19(19), 5381-5389 (2013
145. Di Nicola M, Zappasodi R, Carlostella C, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113(1), 18-27 (2008
146. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotypepulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002
147. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011
148. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327(17), 1209-1215 (1992
149. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999
150. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98(18), 1292-1301 (2006
151. Bendandi M. Idiotype vaccines for lymphoma: proof-ofprinciples and clinical trial failures. Nat. Rev. Cancer 9(9), 675-681 (2009
152. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568-571 (2014
153. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230), 56-61 (2015